Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 32,786,348 | $477,697,090 | -10% | 2.39% |
| 2. | Point72 Asset Management Steve Cohen | 3,697,803 | $53,876,990 | +372% | 0.06% |
| 3. | Millennium Management Israel Englander | 2,349,081 | $34,226,110 | +1761% | 0.01% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,989,591 | $28,988,341 | 0.04% | |
| 5. | Balyasny Asset Management Dmitry Balyasny | 1,904,254 | $27,744,981 | +248% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.12 | 3,810,000 | $49,987,200.00 | 573,883,879 | 2026-06-12 | Filing | |
| $13.12 | 3,810,000 | $49,987,200.00 | 573,883,879 | 2026-06-12 | Filing | |
| $14.60 | 100,000 | $1,460,000.00 | 25,824,474 | 2026-06-04 | Filing | |
| $14.60 | 100,000 | $1,460,000.00 | 25,824,474 | 2026-06-04 | Filing | |
| $14.43 | 25,000 | $360,750.00 | 3,123,603 | 2026-06-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 13,713 | $60,885.72 | 0 | 2020-11-30 | Filing | |
| $4.39 | 29,569 | $129,807.91 | 0 | 2020-11-27 | Filing | |
| $4.32 | 12,070 | $52,142.40 | 0 | 2020-11-25 | Filing | |
| $4.21 | 11,374 | $47,884.54 | 0 | 2020-11-24 | Filing | |
| $4.40 | 6,987 | $30,742.80 | 0 | 2020-11-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,043,947 | $146,340,308 | 0.01% | |
| 2. | 9,536,796 | $138,951,118 | 0% | |
| 3. | 9,529,041 | $138,838,127 | 0% | |
| 4. | 5,734,484 | $83,551,432 | 0% | |
| 5. | 5,233,798 | $76,256,437 | 0.01% |
News See All
10 Most Promising Healthcare Stocks According to Wall Street Analysts
The US healthcare sector has trailed the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
12 Best Buy-the-Dip Stocks to Invest In Now
In this article, we will take a look at some of the best buy-the-dip stocks that are currently offering attractive upside potential. On June 5, CNBC reported that U.S.
10 Best Large Cap Stocks Under $30 With Highest Upside Potential
In this article, we will take a look at some of the best large cap stocks under $30 that are currently offering attractive upside potential.
12 Best High Short Interest Stocks With Highest Upside Potential
On May 29, Melissa Brown, Managing Director of Investment Decision Research, joined BNN Bloomberg to assess the health of the US economy.
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best short squeeze stocks to invest in. On May 22, Cantor Fitzgerald restated its Overweight rating for Summit Therapeutics Inc. (NASDAQ:SMMT).
10 Stocks Entering June in the Wrong Direction
Qualcomm snapped a two-day winning streak on Monday, shedding 8.78 percent to finish at $228.99 apiece, as investors resorted to profit-taking following the previous trading day’s record high, while...
13 Best Short Squeeze Stocks to Invest In
US markets climbed to record highs, wrapping up a solid month, as President Trump announced he will soon make a decision on the Iran deal.
8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
10 Best Stocks to Buy in a Rising Market According to Wall Street Analysts
The equity market remains bullish, driven by a record-setting trend fueled by renewed enthusiasm for artificial intelligence.
Hedge Fund Resource Center